Prior to initiating treatment, verify pregnancy status in females of reproductive potential.
- TRADE NAME: Brexafemme (Scynexis)
- INDICATIONS: Vulvovaginal candidiasis
- CLASS: Antifungal / antimycotic, Antimicrobial
- HALF-LIFE: approximately 20 hours
- FDA APPROVAL DATE: 06/01/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Bosentan, Carbamazepine, CYP3A inducers, CYP3A inhibitors, Efavirenz, Etravirine, Itraconazole, Ketoconazole, long acting barbiturates , Phenytoin, Rifampin, St John's Wort - PREGNANCY: May cause fetal harm based on animal studies. Advise females of reproductive potential to use effective contraception during treatment.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
